<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15652">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00123955</url>
  </required_header>
  <id_info>
    <org_study_id>AG0030</org_study_id>
    <secondary_id>R01AG018915</secondary_id>
    <secondary_id>2R01 AG018915-05</secondary_id>
    <nct_id>NCT00123955</nct_id>
  </id_info>
  <brief_title>PIE II: Pharmacological Intervention in the Elderly II</brief_title>
  <official_title>Exercise Intolerance in Elderly Diastolic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest School of Medicine</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether spironolactone will improve exercise
      tolerance and quality of life in elderly patients with heart failure preserved ejection
      fraction (HFPEF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exercise intolerance due to HFPEF is a major cause of disability among older Americans.
      Several lines of evidence suggest that aldosterone antagonism may improve exercise tolerance
      in HFPEF. Therefore, the primary aim of this study is to test the hypothesis that
      spironolactone will improve exercise tolerance and quality of life in elderly patients with
      isolated HFPEF. A total of 72 participants aged 60 or older will be randomized to receive
      either spironolactone 25mg daily or a placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Exercise Intolerance</measure>
    <time_frame>Baseline, 4 and 9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Peak exercise VO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Baseline, 4 and 9 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentric Left Ventricular Remodeling</measure>
    <time_frame>Baseline, 4 and 9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Diastolic Stiffness</measure>
    <time_frame>Baseline, 4 and 9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Diastolic Heart Failure</condition>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spironolactone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>25mg tablet daily for 9 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Aldactone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet daily for 9 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory

          -  Medically stable

          -  Ages 60 or older

          -  Diagnosis of diastolic heart failure

        Exclusion Criteria:

          -  Valvular heart disease

          -  Significant change in cardiac medication within the past 4 weeks

          -  Uncontrolled hypertension

          -  Recent or debilitating stroke

          -  Cancer or other noncardiovascular conditions with life expectancy less than 2 years

          -  Anemia

          -  Elevated serum potassium

          -  Renal insufficiency

          -  Psychiatric disease (uncontrolled major psychoses, depression, dementia, or
             personality disorder)

          -  Allergy to spironolactone; currently taking spironolactone or any aldosterone
             antagonist

          -  Plans to leave area within 1 year

          -  Refuses informed consent

          -  Failure to pass screening tests: pulmonary function, echocardiogram, or exercise

          -  Contra-indications to magnetic resonance imaging [MRI] (indwelling metal-containing
             prosthesis; pacemaker or defibrillator; history of welding occupation; uncontrollable
             claustrophobia)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalane W. Kitzman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Internal Medicine, Cardiology, Director of Echocardiography, Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan B, Morgan TM, Stewart KP. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002 Nov 6;288(17):2144-50.</citation>
    <PMID>12413374</PMID>
  </reference>
  <reference>
    <citation>Kitzman DW, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol. 1991 Apr;17(5):1065-72.</citation>
    <PMID>2007704</PMID>
  </reference>
  <reference>
    <citation>Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, Marino EK, Lyles M, Cushman M, Enright PL; Cardiovascular Health Study Research Group. Importance of heart failure with preserved systolic function in patients &gt; or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 2001 Feb 15;87(4):413-9.</citation>
    <PMID>11179524</PMID>
  </reference>
  <reference>
    <citation>Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000 Nov 28;102(22):2700-6. Erratum in: Circulation 2001 Jan 23;103(3):476.</citation>
    <PMID>11094035</PMID>
  </reference>
  <reference>
    <citation>Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17.</citation>
    <PMID>10471456</PMID>
  </reference>
  <reference>
    <citation>Cicoira M, Zanolla L, Franceschini L, Rossi A, Golia G, Zeni P, Caruso B, Zardini P. Relation of aldosterone &quot;escape&quot; despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2002 Feb 15;89(4):403-7.</citation>
    <PMID>11835920</PMID>
  </reference>
  <reference>
    <citation>Kitzman DW, Herrington DM, Brubaker PH, Moore JB, Eggebeen J, Haykowsky MJ. Carotid arterial stiffness and its relationship to exercise intolerance in older patients with heart failure and preserved ejection fraction. Hypertension. 2013 Jan;61(1):112-9. doi: 10.1161/HYPERTENSIONAHA.111.00163. Epub 2012 Nov 12.</citation>
    <PMID>23150511</PMID>
  </reference>
  <reference>
    <citation>Daniel KR, Wells G, Stewart K, Moore B, Kitzman DW. Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest Heart Fail. 2009 Mar-Apr;15(2):68-74. doi: 10.1111/j.1751-7133.2009.00056.x.</citation>
    <PMID>19379452</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 23, 2015</lastchanged_date>
  <firstreceived_date>July 22, 2005</firstreceived_date>
  <firstreceived_results_date>February 6, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wake Forest School of Medicine</investigator_affiliation>
    <investigator_full_name>Dalane W. Kitzman</investigator_full_name>
    <investigator_title>Professor Internal Medicine Cardiology/Gerontology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Spironolactone</title>
          <description>Spironolactone
Spironolactone: 25mg tablet daily for 9 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo tablet daily for 9 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Spironolactone</title>
          <description>Spironolactone
Spironolactone: 25mg tablet daily for 9 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo tablet daily for 9 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
                <measurement group_id="B2" value="38"/>
                <measurement group_id="B3" value="80"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="70.0" spread="7.3"/>
                <measurement group_id="B2" value="71.7" spread="7.3"/>
                <measurement group_id="B3" value="70.8" spread="7.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="64"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Peak VO2 (ml/kg/min)</title>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="13.5" spread="2.9"/>
                <measurement group_id="B2" value="13.3" spread="2.9"/>
                <measurement group_id="B3" value="13.4" spread="2.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Workload (Watts)</title>
          <units>Watts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63" spread="26"/>
                <measurement group_id="B2" value="60" spread="26"/>
                <measurement group_id="B3" value="62" spread="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exercise Intolerance</title>
        <description>Peak exercise VO2</description>
        <time_frame>Baseline, 4 and 9 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>The outcome measure data uses data from all participants with 4 and/or 9 month follow-up. Thirty-seven participants randomized to spironolactone and 35 participants randomized to placebo completed 4 months of follow-up, and 37 participants randomized to spironolactone and 34 participants randomized to placebo completed 9 months of follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Spironolactone</title>
            <description>Spironolactone
Spironolactone: 25mg tablet daily for 9 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo tablet daily for 9 months</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Exercise Intolerance</title>
            <description>Peak exercise VO2</description>
            <units>ml/kg/min</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.5" spread="2.9"/>
                  <measurement group_id="O2" value="13.3" spread="2.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4 months</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.6" spread="3.5"/>
                  <measurement group_id="O2" value="13.5" spread="3.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>9 months</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.8" spread="3.2"/>
                  <measurement group_id="O2" value="13.9" spread="3.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Quality of Life</title>
        <time_frame>Baseline, 4 and 9 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentric Left Ventricular Remodeling</title>
        <time_frame>Baseline, 4 and 9 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Diastolic Stiffness</title>
        <time_frame>Baseline, 4 and 9 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Spironolactone</title>
          <description>Spironolactone
Spironolactone: 25mg tablet daily for 9 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo tablet daily for 9 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hospitalization for shortness of breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hospitalization for syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hospitalization for hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Elective surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Motor vehicle accident</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dalane Kitzman</name_or_title>
      <organization>Wake Forest Baptist Health</organization>
      <phone>336-716-3274</phone>
      <email>dkitzman@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
